Home LiteratureArticle Details
PMID: 11056681 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group.

Breast cancer research : BCR ·Vol. 1 ·No. 1 ·1999-00-00 ·Pages 73-80

Million Women Study Collaborative Group

Abstract

To describe the design of the Million Women Study and the characteristics of the study population. Population-based cohort study of women aged 50-64 in the UK. Women are asked to join the Million Women Study when they are invited to routine screening for breast cancer at 61 of the screening centres of the UK National Health Service Breast Screening Programme (NHSBSP). An estimated 71% of women screened by the NHSBSP return a completed questionnaire. 800 000 women were recruited between May 1996 and June 1999, and it is planned that an additional 200 000 will be recruited by the year 2000. The characteristics of the first 121 000 women recruited into the Million Women Study are described here. At recruitment 33% of the study population were currently using hormone replacement therapy and 47% had used it at some time. Over half (54%) had used oral contraceptives, and 18% were current smokers at the time of recruitment. Before they were screened 1.4% of the women had been diagnosed with breast cancer in the past, 6% had a mother with a history of breast cancer and 3.7% had a sister with a history of breast cancer. It is estimated that 1 million women will have been recruited by early in the year 2000, and that by the end of the year 2002 there will be 5000 screen-detected breast cancers and 23 000 deaths in the cohort, the majority of which will be attributed to cancer (12 600 deaths) and circulatory disease (8000 deaths). By the end of the year 2002, the Million Women Study will have sufficient statistical power to detect relative risks of 0.8 or less, or of 1.2 or more in current users compared with never users of hormone replacement therapy for mortality from breast cancer, colorectal cancer, lung and ovarian cancer, ischaemic heart disease and stroke.

MeSH Terms
Aged Breast Neoplasms/etiology Cohort Studies Estrogen Replacement Therapy/adverse effects Female Humans Middle Aged United Kingdom
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Million Women Study Collaborative Group
mperial Cancer Research Fund, Cancer Epidemiology Unit, Universityof Oxford, Oxford, UK.
Investigators
23 investigators, click to expand
Beral V
Brown A
Cameron B
Crossley B
Deciacco D
Ewart D
Gerrard L
Hall J
Hall S
Hogg A
Keene C
Langley N
Langston N
Reeves G
Simmonds M
Austoker J
Beral V
English R
Patnick J
Peto R
Reeves G
Vessey M
Reeves G
References (5)
5 references, click to expand
  1. Use of HRT and the subsequent risk of cancer.
    J Epidemiol Biostat. 1999;4(3):191-210; discussion 210-5 PMID: 10695959
  2. Breast cancer screening with mammography: overview of Swedish randomised trials.
    Lancet. 1993 Apr 17;341(8851):973-8 PMID: 8096941
  3. Effect on attendance at breast cancer screening of adding a self administered questionnaire to the usual invitation to breast screening in southern England.
    J Epidemiol Community Health. 1998 Feb;52(2):116-9 PMID: 9578859
  4. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study.
    BMJ. 1999 Jan 9;318(7176):96-100 PMID: 9880284
  5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.
    Lancet. 1997 Oct 11;350(9084):1047-59 PMID: 10213546
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-5411
Published
1999-00-00
Epub
1999-00-19
Pages
73-80
Language
English
Region
England
NLM ID
100927353
PMCID
PMC13913
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com